PMID- 31975647
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20220413
IS  - 1799-7267 (Electronic)
IS  - 1457-4969 (Linking)
VI  - 109
IP  - 1
DP  - 2020 Mar
TI  - Update on the Surgical Treatment of Pancreatic Neuroendocrine Tumors.
PG  - 42-52
LID - 10.1177/1457496919900417 [doi]
AB  - BACKGROUND AND AIMS: Pancreatic neuroendocrine tumors (PNET) arise from 
      uncontrolled proliferation of neuroendocrine cell and further genetic alterations 
      that may induce hormone secretion such as glucagon/insulin/gastrin/VIP. Their 
      incidence is rapidelly growing, especially because of the frequent incidental 
      diagnosis of small asymptomatic non-functionnal neuroendocrine tumors with the 
      widespread use of cross-sectional imaging. The vast majority of pancreatic 
      neuroendocrine tumors are sporadic but up to 5%-10% of them arise from genetic 
      syndromes, the main one being Multiple Endocrine Neopalsm type 1 (MEN1). 
      Appropriate management of patients with PNET is a complex challenge for surgeons, 
      and require extensive medical collaboration. This review aims to summarize major 
      and recent updates regarding the medico-surgical management of PNETs. MATERIAL 
      AND METHODS: Review of pertinent English language literature. RESULTS: This 
      article provides a concise summary of the clinical presentation, diagnosis, 
      surgical management, alternative treatments and follow up of PNETs. CONCLUSION: 
      PNET are a rare, heterogeneous group of neoplasms with a generally favorable 
      prognosis at least compared to pancreatic adenocarcinoma. Surgical resection is 
      the cornerstone of their management, particularly for localized disease, and 
      should always be discussed in multidisciplinary tumor board.
FAU - Jeune, F
AU  - Jeune F
AD  - Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, 
      Pitie Salpetriere Hospital, AP-HP-Pierre and Marie Curie University, Paris VI, 
      France.
FAU - Taibi, A
AU  - Taibi A
AUID- ORCID: 0000-0002-1036-6474
AD  - Department of Digestive and Endocrine surgery, Dupuytren University Hospital, 
      Limoges, France.
FAU - Gaujoux, S
AU  - Gaujoux S
AD  - Department of Digestive, Hepato-biliary and Endocrine Surgery, Cochin Hospital 
      AP-HP, Paris, France.
AD  - Faculte de Medecine Paris Descartes, Universite Paris Descartes, Universite 
      Sorbonne Paris Cite, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200124
PL  - England
TA  - Scand J Surg
JT  - Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical 
      Society and the Scandinavian Surgical Society
JID - 101144297
SB  - IM
MH  - Aftercare
MH  - Humans
MH  - Neuroendocrine Tumors/diagnosis/*surgery/therapy
MH  - Pancreatectomy
MH  - Pancreatic Neoplasms/diagnosis/*surgery/therapy
MH  - Prognosis
OTO - NOTNLM
OT  - Pancreatic neuroendocrine tumor
OT  - diagnosis
OT  - follow-up
OT  - management
OT  - pancreatic radiofrequency ablation
OT  - pancreatic surgery
EDAT- 2020/01/25 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/01/25 06:00
PHST- 2020/01/25 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/01/25 06:00 [entrez]
AID - 10.1177/1457496919900417 [doi]
PST - ppublish
SO  - Scand J Surg. 2020 Mar;109(1):42-52. doi: 10.1177/1457496919900417. Epub 2020 Jan 
      24.